Insulet downgraded at Oppenheimer on growing risks

· seekingalpha.com

Oppenheimer downgrades Insulet on softer growth outlook and type 2 diabetes concerns. Read more here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

If you have an ad-blocker enabled you may be blocked from ...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI